Refine by
Preclinical Modeling Suppliers & Manufacturers
32 companies found
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator.44 This activation is thought to starve cancer cells of important molecular building blocks, inhibiting tumor cell proliferation, and enhancing antitumor ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
Once ADCs release their cytotoxic payload into targeted cells, the drug is often able to cross cell membranes, entering and potentially killing neighboring cells whether those cells are cancerous or not. This effect is called bystander-killing, ...
based inBoston, MASSACHUSETTS (USA)
At Emulate, we understand that animal studies and reductionist models are limited because they are not based on integrated human biology. By leveraging 21st century technologies, we are able to overcome these limitations with living human in vitro ...
Investigate mechanisms of toxicity for preclinical drug candidates to help decrease clinical trial safety failures. Drug-induced liver injury (DILI) is a primary concern during drug development that remains poorly understood due to ...
based inSan Diego, CALIFORNIA (USA)
Everyone at AnaBios shares a passion and commitment to make a difference in the development of promising new therapies and cures for patients by reducing the time and expense needed to bring these medicines to patients. We do this by generating ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
based inMountain View, CALIFORNIA (USA)
ClearLight Biotechnologies provides contract research and development services to pharmaceutical companies who seek to improve the efficacy of potential drug candidates. The company provides pharmaceutical, biotechnology, and academic researchers ...
based inMalvern, PENNSYLVANIA (USA)
We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase ...
Harnessing the Anticancer Power of Hydrogen Peroxide: As cancer cells are more susceptible than normal cells to increased levels of hydrogen peroxide, we believe the conversion of radiation-generated superoxide to hydrogen peroxide by our selective ...
based inSouth Melbourne, AUSTRALIA
BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. Our business model is to generate income from partnerships including with other vaccine and infectious ...
BDM-I: Addressing market need for next-generation antimicrobials. Infectious diseases often dominate the media headlines, including rising antibiotic resistance and fear of “super bugs”. One serious problem facing the global community is ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting ...
based inHeerlen, NETHERLANDS
DSM is a global purpose-led, science-based company specializing in Nutrition, Health & Sustainable Living. Our purpose is to create brighter lives for all. We achieve it by using all the scientific and innovation power at our disposal to tackle some ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
Innovative antibody-based molecular concepts. New treatments for cancer that leverage our own immune system to attack and destroy cancer cells can provide long-term and durable therapeutic responses in patients suffering from life-threatening ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several ...
based inSouth San Francisco, CALIFORNIA (USA)
Neurona Therapeutics is driven by rigorous scientific discovery and focused on developing breakthrough treatments for neurological disorders. Neurona Therapeutics is a privately-held, clinical-stage biotherapeutics company focused on discovering and ...
Chronic Disorders of the Nervous System are Prime Indications for Regenerative Medicine. Neurona is a clinical-stage biotherapeutics company developing regenerative cell therapies that permanently integrate into neural circuits, replace affected ...
based inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
MT-303 represents the first candidate in a new therapeutic modality targeting hepatocellular carcinoma (HCC). Liver cancer is a prevalent and challenging cancer with over 850,000 new cases diagnosed globally each year, and the third leading cause of ...
based inNess Ziona, ISRAEL
Science in Action (SIA) is a boutique preclinical contract research organization (CRO) founded in 2010 by immunologist Raanan Margalit. SIA is GLP-accredited for toxicology studies in multiple areas. SIA has extensive experience in tailor-made ...
based inAnkara, TURKEY
Nisan Medical is successfully operating in the industry for almost 30 years. They are especially creating turnkey hospital projects all around Turkey and operate the application. They work with key business partners for Central Sterilization Units ...
based inBillerica, MASSACHUSETTS (USA)
Access Vascular is offering a suite of vascular access devices that use our novel, patented biomaterial featuring MIMIX™ technology which is designed to prevent the most common and costly complications in vascular access. Keep treatment moving ...
based inCambridge, UNITED KINGDOM
CN Bio is a leading bioengineering company specialising in single and multi-organ microphysiological systems and innovative lab technologies. We aim to provide systems that generate clinically translatable data that can enhance the development of ...
based inLa Tronche, FRANCE
INOVOTION is a Contract Research Laboratory implementing a unique approach to in vivo evaluation for anticancer drug discovery. Our cutting-edge proprietary technology provides early analysis of your compounds before the classical preclinical stage. ...
based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Focusing initially on breast cancer, BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight cancer. ...
